<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">683258</article-id><article-id pub-id-type="doi">10.26442/00403660.2025.10.203371</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Contemporary capabilities of CT texture analysis in the diagnosis of pheochromocytoma: associations with clinical, laboratory, and pathomorphological findings</article-title><trans-title-group xml:lang="ru"><trans-title>Современные возможности текстурного анализа КТ-изображений в диагностике феохромоцитом: связь с клинико-лабораторными и патоморфологическими данными</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7965-9454</contrib-id><name-alternatives><name xml:lang="en"><surname>Tarbaeva</surname><given-names>Natalia V.</given-names></name><name xml:lang="ru"><surname>Тарбаева</surname><given-names>Наталья Викторовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>канд. мед. наук, врач-рентгенолог, зав. отд-нием компьютерной и магнитно-резонансной томографии</p></bio><email>ntarbaeva@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-8035-676X</contrib-id><name-alternatives><name xml:lang="en"><surname>Manaev</surname><given-names>Almaz V.</given-names></name><name xml:lang="ru"><surname>Манаев</surname><given-names>Алмаз Вадимович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>мед. физик, аспирант</p></bio><email>ntarbaeva@inbox.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5592-4794</contrib-id><name-alternatives><name xml:lang="en"><surname>Chevais</surname><given-names>Anastassia</given-names></name><name xml:lang="ru"><surname>Шевэ</surname><given-names>Анастасия</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>канд. мед. наук, врач-эндокринолог</p></bio><email>ntarbaeva@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7098-4584</contrib-id><name-alternatives><name xml:lang="en"><surname>Beltsevich</surname><given-names>Dmitry G.</given-names></name><name xml:lang="ru"><surname>Бельцевич</surname><given-names>Дмитрий Германович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д-р мед. наук, гл. науч. сотр.</p></bio><email>ntarbaeva@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6891-0009</contrib-id><name-alternatives><name xml:lang="en"><surname>Urusova</surname><given-names>Liliya S.</given-names></name><name xml:lang="ru"><surname>Урусова</surname><given-names>Лилия Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д-р мед. наук, зав. отд-нием фундаментальной патоморфологии</p></bio><email>ntarbaeva@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3951-4338</contrib-id><name-alternatives><name xml:lang="en"><surname>Ebzeeva</surname><given-names>Aminat K.</given-names></name><name xml:lang="ru"><surname>Эбзеева</surname><given-names>Аминат Канаматовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>клин. ординатор</p></bio><email>ntarbaeva@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1857-5083</contrib-id><name-alternatives><name xml:lang="en"><surname>Roslyakova</surname><given-names>Anna A.</given-names></name><name xml:lang="ru"><surname>Рослякова</surname><given-names>Анна Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>врач-эндокринолог</p></bio><email>ntarbaeva@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5634-7877</contrib-id><name-alternatives><name xml:lang="en"><surname>Mel'nichenko</surname><given-names>Galina A.</given-names></name><name xml:lang="ru"><surname>Мельниченко</surname><given-names>Галина Афанасьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>акад. РАН, д-р мед. наук, проф., зав. каф. клинической эндокринологии Института высшего и дополнительного профессионального образования, зам. дир. Центра по научной работе</p></bio><email>ntarbaeva@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9717-9742</contrib-id><name-alternatives><name xml:lang="en"><surname>Mokrysheva</surname><given-names>Natalia G.</given-names></name><name xml:lang="ru"><surname>Мокрышева</surname><given-names>Наталья Георгиевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>акад. РАН, д-р мед. наук, проф., зав. каф. персонализированной и трансляционной медицины, дир.</p></bio><email>ntarbaeva@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Endocrinology Research Centre</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр эндокринологии им. акад. И.И. Дедова» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">National Research Nuclear University MEPhI</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Национальный исследовательский ядерный университет “МИФИ“»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-11-11" publication-format="electronic"><day>11</day><month>11</month><year>2025</year></pub-date><volume>97</volume><issue>10</issue><issue-title xml:lang="en">Issues of endocrinology</issue-title><issue-title xml:lang="ru">Вопросы эндокринологии</issue-title><fpage>844</fpage><lpage>858</lpage><history><date date-type="received" iso-8601-date="2025-06-06"><day>06</day><month>06</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-07-02"><day>02</day><month>07</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/683258">https://ter-arkhiv.ru/0040-3660/article/view/683258</self-uri><abstract xml:lang="en"><p><bold>Aim.</bold> To investigate the presence of statistically significant correlations between clinical and laboratory characteristics and features of contrast-enhanced computed tomography (CT) images, as well as to assess the possibility of predicting group classification according to the PASS scale based on clinical, laboratory, and contrast-enhanced CT imaging data.</p> <p><bold>Materials and methods.</bold> A retrospective analysis was performed on preoperative four-phase contrast-enhanced CT images of 230 patients with a pathomorphologically verified diagnosis of pheochromocytoma/paraganglioma. Clinical manifestations such as the presence and duration of arterial hypertension, carbohydrate metabolism disorders, and dyslipidemia were assessed. In the first stage, comparative and correlation analyses were conducted between hormonal parameters and contrast-enhanced CT data. In the second stage, based on morphological characteristics, patients were divided into two groups: with PASS scores &lt;4 (<italic>n</italic>=155) and PASS scores ≥4 (<italic>n</italic>=56). Logistic regression analysis was conducted to evaluate the possibility of predicting group classification based on clinical, laboratory, and contrast-enhanced CT imaging data.</p> <p><bold>Results.</bold> Pheochromocytomas/paragangliomas with isolated normetanephrine secretion type accumulate significantly more contrast agent in the arterial and venous phases of the study (<italic>p</italic>&lt;0.001) compared to other secretion types. Correlation analysis revealed statistically significant moderate positive correlations between blood normetanephrine levels and the volume of functioning tumor tissue without necrotic areas, as well as a moderate negative correlation between blood metanephrine levels and the maximum density in the venous phase, the percentage of venous contrast enhancement, and the 90th percentile of X-ray density of the functioning tumor tissue in the venous CT phase. A statistically significant association was also found between the presence/absence of necrosis and tumor size (<italic>p</italic>&lt;0.001), as well as between structure and tumor size (<italic>p</italic>=0.004). No statistically significant correlations were identified between laboratory parameters, imaging data, and clinical manifestations (arterial hypertension, carbohydrate metabolism disorders, dyslipidemia, and carotid artery atherosclerosis). CT image characteristics allow for prediction of group classification according to the PASS scale with an AUC of 0.647 (95% confidence interval 0.471–0.797), sensitivity of 0.923 (0.727–1.000), specificity of 0.400 (0.250–0.548), PPV of 0.333 (0.176–0.500), and NPV of 0.941 (0.800–1.000).</p> <p><bold>Conclusion.</bold> Pheochromocytomas/paragangliomas are heterogeneous pathologies with diverse clinical, hormonal, and radiological characteristics that are associated with pathomorphological findings (PASS scale).</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель.</bold> Исследовать наличие статистически значимых взаимосвязей между клинико-лабораторными характеристиками и признаками изображений компьютерной томографии (КТ) с контрастным усилением (КУ), а также оценить возможности прогноза по клинико-лабораторным данным и данным изображений КТ с КУ разделения на группы согласно шкале PASS.</p> <p><bold>Материалы и методы.</bold> Проведен ретроспективный анализ предоперационных изображений четырехфазного КТ с КУ 230 пациентов с патоморфологически верифицированным диагнозом «феохромоцитома/параганглиома» (ФХЦ/ПГ). В качестве клинических проявлений оценивались наличие и длительность артериальной гипертензии, нарушений углеводного обмена и дислипидемии. Первым этапом проведен сравнительный и корреляционный анализ между гормональными показателями и КТ с КУ. Вторым этапом при анализе морфологических характеристик пациенты разделены на 2 группы: с баллами по шкале PASS&lt;4 (<italic>n</italic>=155) и PASS≥4 (<italic>n</italic>=56), проведен логистический регрессионный анализ для определения возможности прогноза группы по клинико-лабораторным данным и характеристикам изображений КТ с КУ.</p> <p><bold>Результаты.</bold> ФХЦ/ПГ с изолированным норметанефриновым типом секреции статистически значимо копят больше контрастного вещества в артериальную и венозную фазы исследования (<italic>p</italic>&lt;0,001) по сравнению с другими типами секреции. В результате корреляционного анализа выявлены статистически значимые положительные умеренные корреляции между уровнем норметанефрина крови и объемом функционирующей опухолевой ткани без зон распада, а также отрицательная умеренная корреляция между уровнем метанефрина крови и максимальной плотностью в венозную фазу исследования, процентом венозного накопления контраста и 90-м перцентилем рентгеновской плотности функционирующей ткани опухоли в венозную фазу КТ. Также обнаружена статистически значимая связь между наличием/отсутствием некрозов и размерами образования (<italic>p</italic>&lt;0,001), структурой и размерами образования (<italic>p</italic>=0,004). При анализе возможных корреляций между лабораторными показателями, инструментальными данными и клиническими проявлениями (артериальная гипертензия, нарушения углеводного обмена, дислипидемия и атеросклероз брахиоцефальных артерий) статистически значимых корреляций не выявлено. Характеристики изображений КТ позволяют спрогнозировать разделение на группы согласно шкале PASS с AUC 0,647 (95% доверительный интервал 0,471–0,797), чувствительностью 0,923 (0,727–1,000), специфичностью 0,400 (0,250–0,548), PPV 0,333 (0,176–0,500), NPV 0,941 (0,800–1,000).</p> <p><bold>Заключение.</bold> ФХЦ/ПГ является гетерогенной патологией с различными клиническими, гормональными и радиологическими характеристиками, связанными с патоморфологическими данными (шкала PASS).</p></trans-abstract><kwd-group xml:lang="en"><kwd>рheochromocytoma/рaraganglioma</kwd><kwd>CT characteristics</kwd><kwd>metanephrine</kwd><kwd>normetanephrine</kwd><kwd>texture analysis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>феохромоцитома/параганглиома</kwd><kwd>КТ-характеристики</kwd><kwd>метанефрин</kwd><kwd>норметанефрин</kwd><kwd>текстурный анализ</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915-42. DOI:10.1210/jc.2014-1498</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Kiriakopoulos A, Giannakis P, Menenakos E. Pheochromocytoma: a changing perspective and current concepts. Ther Adv Endocrinol Metab. 2023;14:20420188231207544. DOI:10.1177/20420188231207544</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Lloyd R, Osamura R, Kloppel G, Rosai J. WHO classification of tumours of endocrine organs. 4th ed. Lyon: International Agency for Research on Cancer, 2017.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>WHO Classification of Tumours Editorial Board. Endocrine and neuroendocrine tumours. Vol. 8. 5th ed. Lyon: International Agency for Research on Cancer; 2022. Available at: https://tumourclassification.iarc.who.int. Accessed: 22.01.2025.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Nölting S, Bechmann N, Taieb D, et al. Personalized management of pheochromocytoma and paraganglioma. Endocr Rev. 2022;43(2): 199-239. DOI:10.1210/endrev/bnab019</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Snezhkina A, Pavlov V, Dmitriev A, et al. Potential biomarkers of metastasizing paragangliomas and pheochromocytomas. Life (Basel). 2021;11(11):1179. DOI:10.3390/life11111179</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Thompson LD. Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol. 2002;26(5):551-66. DOI:10.1097/00000478-200205000-00002</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Kimura N, Takayanagi R, Takizawa N, et al. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2014;21:405-14. DOI:10.1530/ERC-13-0494</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Pierre C, Agopiantz M, Brunaud L, et al. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas. Virchows Arch. 2019;474(6):721-34. DOI:10.1007/s00428-019-02553-5</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Cho YY, Kwak MK, Lee SE, et al. A clinical prediction model to estimate the metastatic potential of pheochromocytoma/paraganglioma: ASES score. Surgery. 2018;164(3):511-17. DOI:10.1016/j.surg.2018.05.001</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Wachtel H, Hutchens T, Baraban E, et al. Predicting metastatic potential in pheochromocytoma and paraganglioma: a comparison of PASS and GAPP scoring systems. J Clin Endocrinol Metab. 2020;105(12): e4661-70. DOI:10.1210/clinem/dgaa608</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Stenman A, Zedenius J, Juhlin CC. The value of histological algorithms to predict the malignancy potential of pheochromocytomas and abdominal paragangliomas: a meta-analysis and systematic review. Cancers (Basel). 2019;11(2):225. DOI:10.3390/cancers11020225</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Aygun N, Uludag M. Pheochromocytoma and Paraganglioma: From Epidemiology to Clinical Findings. Sisli Etfal Hastan Tip Bul. 2020;54(2):159-68. DOI:10.14744/SEMB.2020.18794</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Buitenwerf E, Korteweg T, Visser A, et al. Unenhanced CT imaging is highly sensitive to exclude pheochromocytoma: A multicenter study. Eur J Endocrinol. 2018;5(178):431-7. DOI:10.1530/EJE-18-0006</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Canu L, Van Hemert JAW, Kerstens MN, et al. CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma. J Clin Endocrinol Metab. 2019;104(2):312-8. DOI:10.1210/jc.2018-01532</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Falhammar H, Kjellman M, Calissendorff J. Initial clinical presentation and spectrum of pheochromocytoma: A study of 94 cases from a single center. Endocr Connect. 2018;7:186-92. DOI:10.1530/EC-17-0321</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Guerrero MA, Schreinemakers JM, Vriens MR, et al. Clinical spectrum of pheochromocytoma. J Am Coll Surg. 2009;209:727-32. DOI:10.1016/j.jamcollsurg.2009.09.022</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Eisenhofer G, Lenders JW, Goldstein DS, et al. Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. Clin Chem. 2005;51:735-44. DOI:10.1373/clinchem.2004.045484</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Ohara N, Uemura Y, Mezaki N, et al. Histopathological analysis of spontaneous large necrosis of adrenal pheochromocytoma manifested as acute attacks of alternating hypertension and hypotension: a case report. J Med Case Rep. 2016;10(1):279. DOI:10.1186/s13256-016-1068-3</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Mohamed HA, Aldakar MO, Habib N. Cardiogenic shock due to acute hemorrhagic necrosis of a pheochromocytoma: a case report and review of the literature. Can J Cardiol. 2003;19:573-6.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Amar L, Baudin E, Burnichon N, et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab. 2007;92(10):3822-8. DOI:10.1210/jc.2007-0709</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Turkova H, Prodanov T, Maly M, et al. Characteristics and outcomes of metastatic SDHB and sporadic pheochromocytoma/paraganglioma: an National Institutes of Health study. Endocr Pract. 2016;22(3):302-14. DOI:10.4158/EP15725.OR</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Юкина М.Ю., Трошина Е.А., Бельцевич Д.Г., и др. Феохромоцитома/параганглиома: клинико-генетические аспекты. Проблемы эндокринологии. 2013;59(3):19-26 [Iukina MIu, Troshina EA, Bel'tsevich DG, et al. Pheochromocytoma/paraganglioma: clinical and genetic aspects. Problems of Endocrinology. 2013;59(3):19-26 (in Russian)].</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Gild ML, Do K, Tsang VHM, et al. Pheochromocytoma in MEN2. Recent Results. Cancer Res. 2025;223:211-35. DOI:10.1007/978-3-031-80396-3_8</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Eisenhofer G, Walther MM, Huynh TT, et al. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab. 2001;86(5):1999-2008. DOI:10.1210/jcem.86.5.7496</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>De Leo A, Vara G, Paccapelo A, et al. Computerized tomography texture analysis of pheochromocytoma: relationship with hormonal and histopathological data. J Endocrinol Invest. 2022;45(10):1935-44. DOI:10.1007/s40618-022-01826-2</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Crimì F, Agostini E, Toniolo A, et al. CT texture analysis of adrenal pheochromocytomas: a pilot study. Curr Oncol. 2023;30(2):2169-77. DOI:10.3390/curroncol30020167</mixed-citation></ref></ref-list></back></article>
